TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11104592

Group type: EXPERIMENTAL
Intervention: Early postoperative gastric supply of nutrients (Osmolite, Ross; first 3 hours 30 ml/h and second 3 hours 50 ml/h; total 240 ml after 6 hours)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (crystalloid solutions only)
Number of subjects: 80
Study: 9557493

Group type: EXPERIMENTAL
Intervention: Cetirizine (early therapeutic intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged breast feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 8142781

Group type: EXPERIMENTAL
Intervention: EMLA cream (eutectic mixture of local anesthetics) applied for 3 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study: 2873397

Group type: EXPERIMENTAL
Intervention: Oral B subunit killed whole‐cell (BS‐WC) vaccine
Number of subjects: 63498

Group type: EXPERIMENTAL
Intervention: Killed whole‐cell (WC) vaccine
Number of subjects: 63498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63498
Study: 30614403

Group type: EXPERIMENTAL
Intervention: HOPE intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (Facebook) group
Number of subjects: 51
Study: 26469395

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 minutes for 5 consecutive days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 20
Study: 25530675

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) at 1 mA for 20 minutes over the left dorsolateral prefrontal cortex (F3) for 5 consecutive days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 20
Study: 23116986

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study: 20474068

Group type: EXPERIMENTAL
Intervention: Mothers with T1D
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Mothers without T1D
Number of subjects: 2160
Study: 19047671

Group type: EXPERIMENTAL
Intervention: 5,000 ppm fluoride dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1,100 ppm fluoride dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No fluoride dentifrice
Number of subjects: 0
Study: 15670563

Group type: EXPERIMENTAL
Intervention: Oral methionine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12601318

Group type: EXPERIMENTAL
Intervention: Budesonide (Rhinocort AQUA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mometasone (Nasonex)
Number of subjects: 20
Study: 10488698

Group type: EXPERIMENTAL
Intervention: HCV seropositive women with detectable HCV RNA in serum (n = 16)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HCV seropositive non-viremic patients (n = 6)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (11 HCV seronegative women)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Children of the women tested (n = 10)
Number of subjects: 22
Study: 8947993

Group type: EXPERIMENTAL
Intervention: Bromfenac 5, 10, 25, 50, or 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromfenac in mouse pain model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromfenac 50 mg
Number of subjects: 0
Study: 1915199

Group type: EXPERIMENTAL
Intervention: Protein hydrolysate diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intact protein diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 32
Study: 31564057

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Dupilumab with topical corticosteroids
Number of subjects: 250
Study: 29483085

Group type: EXPERIMENTAL
Intervention: Low-calorie vegetarian diet (Vd)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low-calorie Mediterranean diet (MD)
Number of subjects: 118
Study: 27759648

Group type: EXPERIMENTAL
Intervention: Preoperative acute lung injury (ALI) assessment
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Perioperative clinical baselines and serum variables assessment
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis
Number of subjects: 130
Study: 25099941

Group type: EXPERIMENTAL
Intervention: Interval Walking Training (IWT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continuous Walking Training (CWT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 32
Study: 22039269

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CS injection)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Percutaneous release
Number of subjects: 137

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 137
Study: 20929584

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) - 429‐559 kcal/day liquid formula for 4 weeks after quitting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Individual Dietary and Activity Planning (IDAP) - goal-setting with a daily reduction of 600 kcal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual dietary advice (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 and 12 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weight, waist and hip circumference, percentage body fat
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abstinence confirmed by CO < 10 ppm
Number of subjects: 30
Study: 17804169

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 82

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 82
Study: 17180869

Group type: EXPERIMENTAL
Intervention: Fatty acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12831415

Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study: 10771456

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg day(‐1) on days 9‐11 followed by 80 mg day(‐1) on days 12‐15
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9387729

Group type: EXPERIMENTAL
Intervention: Zhenkeling oral liquor (ZKL group)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Pectoral syrup (control group)
Number of subjects: 170
Study: 1343611

Group type: EXPERIMENTAL
Intervention: Weekly oral low-dose (7.5 mg) methotrexate (MTX) for 2 years
Number of subjects: 100

Group type: COMPARATOR
Intervention: Identical-appearing placebo for 2 years
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Weekly oral low-dose (7.5 mg) methotrexate (MTX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Identical-appearing placebo
Number of subjects: 100
Study: 2864738

Group type: EXPERIMENTAL
Intervention: Gastric inhibitory polypeptide (GIP) in pharmacological doses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) in pharmacological doses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Somatostatin in pharmacological doses
Number of subjects: 6
Study: 30880951

Group type: EXPERIMENTAL
Intervention: batefenterol 37.5 µg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: batefenterol 75 µg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: batefenterol 150 µg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: batefenterol 300 µg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: batefenterol 600 µg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg
Number of subjects: 323

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 323
Study: 29526609

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (iENGAGE) focusing on retention in care and ART adherence skills during the first year of HIV care.
Number of subjects: 0
Study: 27197523

Group type: EXPERIMENTAL
Intervention: Goserelin plus tamoxifen for 2 years and 5 years of tamoxifen
Number of subjects: 1483

Group type: COMPARATOR
Intervention: Tamoxifen alone for 5 years
Number of subjects: 1483
Study: 24344049

Group type: EXPERIMENTAL
Intervention: Mangifera indica extract (Vimang tablets, 900 mg/day) combined with methotrexate (MTX, 12.5 mg/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methotrexate (MTX, 12.5 mg/week) without Vimang extract
Number of subjects: 20
Study: 22743029

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham Cryotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 36
Study: 20585287

Group type: EXPERIMENTAL
Intervention: Vibration Group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 34
Study: 17474183

Group type: EXPERIMENTAL
Intervention: Cholinergic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMDA agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive interventions including rehabilitation pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drugs strategically coupled to cognitive-behavioral treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control of vascular risk factors
Number of subjects: 0
Study: 16136052

Group type: EXPERIMENTAL
Intervention: Chemotherapy started within 3 months of surgery (CMF, CMF i.v., cyclofosfamide, epirubicin, and 5‐fluorouracil)
Number of subjects: 7501

Group type: COMPARATOR
Intervention: Chemotherapy started after 3 months of surgery (delayed start)
Number of subjects: 7501
Study: 12182269

Group type: EXPERIMENTAL
Intervention: Patients' expectancies of treatment effectiveness
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Therapists' expectancies for patient improvement
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Quality of therapeutic alliance
Number of subjects: 151
Study: 10460813

Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 302

Group type: COMPARATOR
Intervention: Initial medical stabilization
Number of subjects: 302
Study: 8552460

Group type: EXPERIMENTAL
Intervention: Dichorhinic mixtures with delays of 200 to 400 ms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synchronous mixtures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichorhinic mixtures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monorhinic mixtures
Number of subjects: 0
Study: 2140838

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg/day (KE40)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ketanserin 80 mg/day (KE80)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 29
Study: 507944

Group type: EXPERIMENTAL
Intervention: Surgical treatment and oral administration of BCG
Number of subjects: 31

Group type: COMPARATOR
Intervention: Surgical treatment only
Number of subjects: 31
Study: 30715090

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 28397242

Group type: EXPERIMENTAL
Intervention: Ibrutinib with concomitant anticoagulation (11%)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Ibrutinib with concomitant antiplatelet use (34%)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Ibrutinib with concomitant anticoagulant or antiplatelet agents (175 patients)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Ibrutinib alone (without anticoagulants or antiplatelets)
Number of subjects: 327
Study: 26362110

Group type: EXPERIMENTAL
Intervention: Oral collagen peptide supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex vivo collagen peptide supplementation
Number of subjects: 0
Study: 23017096

Group type: EXPERIMENTAL
Intervention: Stop signal intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 21586691

Group type: EXPERIMENTAL
Intervention: Resolute
Number of subjects: 353

Group type: COMPARATOR
Intervention: Endeavor
Number of subjects: 353

Group type: COMPARATOR
Intervention: ZoMaxx
Number of subjects: 353

Group type: COMPARATOR
Intervention: Driver
Number of subjects: 353
Study: 19389002

Group type: EXPERIMENTAL
Intervention: First 19 unsupervised procedures after training
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Next 20-99 procedures
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Last 100 procedures
Number of subjects: 3011
Study: 16466358

Group type: EXPERIMENTAL
Intervention: Individualized, developmentally supportive family-centered care
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Routine care plus individualized, developmentally supportive family-centered interventions
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine neonatal intensive-care unit standard of care
Number of subjects: 114
Study: 15307407

Group type: EXPERIMENTAL
Intervention: Community-based intervention to improve skills of village drug kit managers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 0
Study: 10392251

Group type: EXPERIMENTAL
Intervention: Fibrin glue treatment
Number of subjects: 10
Study: 8678535

Group type: EXPERIMENTAL
Intervention: Arm T (THP + CPA + TAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arm C (CPA + TAM)
Number of subjects: 0
Study: 2072834

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) training (75% of heart rate reserve, approximately 82% VO2max, approximately 121% of lactate threshold)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) training (35% of heart rate reserve, approximately 53% VO2max, approximately 72% of lactate threshold)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (N = 8)
Number of subjects: 17
Study: 6441014

Group type: EXPERIMENTAL
Intervention: Standard polyethylene catheter plus heparin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polyurethane catheter without heparin
Number of subjects: 40
Study: 30879111

Group type: EXPERIMENTAL
Intervention: Intensified regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Received cumulative dose over time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events in intensified regimen group
Number of subjects: 0
Study: 30270762

Group type: EXPERIMENTAL
Intervention: Intensive aphasia therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26811166

Group type: EXPERIMENTAL
Intervention: Lower fat (20% energy), higher carbohydrate (65% energy) diet
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate (45% energy), higher fat (35% energy) diet
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Walnut-rich, higher fat (35% energy), lower carbohydrate (45% energy) diet
Number of subjects: 245
Study: 24820104

Group type: EXPERIMENTAL
Intervention: Complete immunization schedule (7 vaccines and 15 doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Viral load rebound after cART interruption
Number of subjects: 26
Study: 21987582

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (prednisolone sodium phosphate, 1.0%)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 20661178

Group type: EXPERIMENTAL
Intervention: HPV16 seroprevalence
Number of subjects: 5871

Group type: EXPERIMENTAL
Intervention: HPV18 seroprevalence
Number of subjects: 5871

Group type: EXPERIMENTAL
Intervention: HPV16 DNA prevalence
Number of subjects: 5871

Group type: EXPERIMENTAL
Intervention: HPV18 DNA prevalence
Number of subjects: 5871

Group type: EXPERIMENTAL
Intervention: Correlation with sexual behaviors
Number of subjects: 5871

Group type: EXPERIMENTAL
Intervention: Assay cross-reactivity
Number of subjects: 5871

Group type: EXPERIMENTAL
Intervention: HPV18 seropositivity
Number of subjects: 5871

Group type: EXPERIMENTAL
Intervention: Seroprevalence over time
Number of subjects: 5871

Group type: EXPERIMENTAL
Intervention: Serology as a measure of exposure
Number of subjects: 5871
Study: 17567657

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin for 7 days (n = 126)
Number of subjects: 246

Group type: COMPARATOR
Intervention: IV benzyl penicillin (n = 120)
Number of subjects: 246
Study: 15718308

Group type: EXPERIMENTAL
Intervention: C‐HART (70.6 Gy) with concurrent FU (600 mg/m(2), 120 hours continuous infusion) and MMC (10 mg/m(2))
Number of subjects: 384

Group type: COMPARATOR
Intervention: HART (77.6 Gy)
Number of subjects: 384
Study: 11928803

Group type: EXPERIMENTAL
Intervention: Neoadjuvant and adjuvant chemoradiation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Surgical interventions (resection and reconstruction after esophagectomy)
Number of subjects: 72
Study: 10450301

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (typical American diet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher sodium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate sodium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower sodium intake
Number of subjects: 0
Study: 7539701

Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (5 days)
Number of subjects: 0
Study: 2676220

Group type: EXPERIMENTAL
Intervention: Etidocaine 1% at 2 mg.kg‐1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.5 mg.kg‐1
Number of subjects: 22
Study: 319697

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulators (functioning)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonfunctioning machines (Control)
Number of subjects: 50
Study: 31377534

Group type: EXPERIMENTAL
Intervention: Second Step Child Protection Unit (CPU)
Number of subjects: 2172

Group type: COMPARATOR
Intervention: Control (business as usual)
Number of subjects: 2172
Study: 27484097

Group type: EXPERIMENTAL
Intervention: STNM01 (2.5nM, 25nM, 250nM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: STNM01
Number of subjects: 18
Study: 26051530

Group type: EXPERIMENTAL
Intervention: PVI plus stepwise ablation
Number of subjects: 150

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Stepwise ablation
Number of subjects: 150
Study: 24098633

Group type: EXPERIMENTAL
Intervention: Condition-specific home exercises combined with advice and education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice and education alone (Control)
Number of subjects: 0
Study: 22078153

Group type: EXPERIMENTAL
Intervention: LDA plus naproxen/esomeprazole magnesium (500 mg naproxen and 20 mg esomeprazole magnesium, twice daily on days 6-10)
Number of subjects: 42

Group type: COMPARATOR
Intervention: LDA plus placebo (81 mg LDA once daily on days 1-5 and placebo twice daily on days 6-10)
Number of subjects: 42

Group type: COMPARATOR
Intervention: LDA plus placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LDA plus naproxen/esomeprazole magnesium
Number of subjects: 42
Study: 20146880

Group type: EXPERIMENTAL
Intervention: GEM + BCG
Number of subjects: 87

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 87
Study: 17592345

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 78
Study: 15187778

Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented formula (NT+)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Formula without nucleotides (NT-)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 30
Study: 11289473

Group type: EXPERIMENTAL
Intervention: Metformin (2,550 mg/day for 14 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated obese subjects)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metformin (0.1-0.5 microg/ml) in pooled human plasma
Number of subjects: 10
Study: 9142611

Group type: EXPERIMENTAL
Intervention: Peer review feedback program during the guideline period
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Peer review feedback program during the one-year follow-up period
Number of subjects: 446

Group type: COMPARATOR
Intervention: Preguideline period
Number of subjects: 446
Study: 7634320

Group type: EXPERIMENTAL
Intervention: De Vega's suture annuloplasty
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) guidance during De Vega's annuloplasty
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intraoperative assessment by TEE
Number of subjects: 48
Study: 2792096

Group type: EXPERIMENTAL
Intervention: Modified Labat's technique
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Alternative technique (intersection of hiatus-trochanteric line)
Number of subjects: 224
Study: 1080961

Group type: EXPERIMENTAL
Intervention: Intravenous high dose methotrexate and leucovorin rescue
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 60
Study: 31465401

Group type: EXPERIMENTAL
Intervention: multi-focus compressive sensing (CS) method for 3-D and random-access TPE microscopy using a digital micromirror device (DMD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CS algorithms for reconstructing 3-D images
Number of subjects: 0
Study: 28557555

Group type: EXPERIMENTAL
Intervention: β1 blocker nebivolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study: 26685397

Group type: EXPERIMENTAL
Intervention: Nasal cellulose powder
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physiological sea water
Number of subjects: 36
Study: 23140546

Group type: EXPERIMENTAL
Intervention: Statin treatment in current smokers (n=129)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Patients not on statins (n=720)
Number of subjects: 1600
Study: 21287255

Group type: EXPERIMENTAL
Intervention: FaceSay computer-based social skills training program
Number of subjects: 49
Study: 19543892

Group type: EXPERIMENTAL
Intervention: Cervical TFESI using triamcinolone (particulate steroid)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Cervical TFESI using dexamethasone (non-particulate steroid)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cervical TFESI (general)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Previous operation
Number of subjects: 159